| First Author | Schroeder JH | Year | 2020 |
| Journal | Front Immunol | Volume | 11 |
| Pages | 623324 | PubMed ID | 33603753 |
| Mgi Jnum | J:317401 | Mgi Id | MGI:6805212 |
| Doi | 10.3389/fimmu.2020.623324 | Citation | Schroeder JH, et al. (2020) T-Bet Controls Cellularity of Intestinal Group 3 Innate Lymphoid Cells. Front Immunol 11:623324 |
| abstractText | Innate lymphoid cells (ILC) play a significant immunological role at mucosal surfaces such as the intestine. T-bet-expressing group 1 innate lymphoid cells (ILC1) are believed to play a substantial role in inflammatory bowel disease (IBD). However, a role of T-bet-negative ILC3 in driving colitis has also been suggested in mouse models questioning T-bet as a critical factor for IBD. We report here that T-bet deficient mice had a greater cellularity of NKp46-negative ILC3 correlating with enhanced expression of RORgammat and IL-7R, but independent of signaling through STAT1 or STAT4. We observed enhanced neutrophilia in the colonic lamina propria (cLP) of these animals, however, we did not detect a greater risk of T-bet-deficient mice to develop spontaneous colitis. Furthermore, by utilizing an in vivo fate-mapping approach, we identified a population of T-bet-positive precursors in NKp46-negative ILC3s. These data suggest that T-bet controls ILC3 cellularity, but does do not drive a pathogenic role of ILC3 in mice with a conventional specific pathogen-free microbiota. |
